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ABSTRACT
Aim: To review the management of heart failure in patients not
enrolled in specialist multidisciplinary programs.
Method: A prospective clinical audit of patients admitted to
hospital with either a current or past diagnosis of heart failure
and not enrolled in a specialist heart failure program or under
the direct care of the cardiology unit.
Results: 81 eligible patients were enrolled (1 August to 1
October 2008). The median age was 81 ± 9.4 years and 48%
were male. Most patients (63%) were in New York Heart
Association Class II or Class III heart failure. On discharge,
59% of patients were prescribed angiotensin converting enzyme
inhibitors and 43% were prescribed beta-blockers. During
hospitalisation, 8.6% of patients with a past diagnosis of heart
failure were started on an angiotensin converting enzyme
inhibitor and 4.9% on a beta-blocker. There was evidence of
suboptimal dosage on admission and discharge for angiotensin
converting enzyme inhibitors (19% and 7.4%) and beta-blockers
(29% and 17%). The results compared well with international
reports regarding the under-treatment of heart failure.
Conclusion: The demonstrated practice gap provides excellent
opportunities for the involvement of pharmacists to improve
the continuation of care for heart failure patients discharged
from hospital in the areas of medication management review,
dose titration and monitoring.
J Pharm Pract Res 2009; 39: 186-91.
INTRODUCTION
Many factors contribute to the burden of heart failure
and one of the most important is the limited application
of evidence-based guidelines in heart failure patients not
receiving optimised treatment.1,2 Most heart failure
patients are elderly and have numerous comorbidities,
which often mask symptoms and result in diagnostic
uncertainty and gaps between evidence and practice.1,2
Reports also suggest that only half of the patients treated
for heart failure had their diagnosis confirmed by an
echocardiogram.3 Other barriers to implementing heart
failure evidence into practice include lack of knowledge
and understanding by patients and uncertainty of the
evidence by clinicians.4-6
Guidelines for the management of heart failure that
incorporate pharmacological and non-pharmacological
strategies exist in every region of the world.7-9 Key
pharmacotherapies for the treatment of heart failure
include either an angiotensin converting enzyme inhibitor
or an angiotensin II receptor blocker and a beta-blocker;
and for patients who remain severely symptomatic, the
addition of spironolactone.7-9
In addition, interventions by multidisciplinary teams,
such as monitoring titration of medicines, lifestyle
changes and self-care education, have demonstrated
significant reduction in hospitalisation and readmission
from heart failure.10-16 Non-pharmacological interventions
have demonstrated an improvement in self care, exercise
capacity and quality of life.10-16 Within multidisciplinary
teams, pharmacists have demonstrated that they can
make an important contribution by assisting with the
challenges of managing large and complex medication
regimens.10-16 Despite these positive results, only 8 to
11% of patients with heart failure have access to specialist
heart failure programs and multidisciplinary care.11,17,18
The aim of this study was to review the management
of heart failure in patients not enrolled in specialist
multidisciplinary programs.
METHOD
The study was a prospective clinical audit of heart failure
patients receiving ‘usual care’ at a 640–bed metropolitan
tertiary teaching hospital with around 70 000 admissions
per year. Participants were recruited from the general
medical wards that are part of the hospital’s internal
medical service. Approval to conduct the study was
obtained from the Royal Adelaide Hospital and the
University of Adelaide Human Research Ethics
Committees.
From 1 August to 1 October 2008, admission lists
were screened for eligible patients. Patients were eligible
if they had a current or past diagnosis of heart failure
(left ventricular systolic dysfunction), preserved left
ventricular systolic dysfunction and were not under the
direct care of the cardiology unit. Patients were not
eligible if they had a malignancy, were under palliative
care, enrolled in a heart failure program or admitted to
critical care, intensive care, coronary care or high-
dependency units.
The recommended parameters, contraindications,
special considerations and maximum doses used in heart
failure for angiotensin converting enzyme inhibitors, beta-
blockers and angiotensin II receptor blockers were
adapted from the Australian Medicines Handbook, the
National Heart Foundation/Cardiac Society of Australia
and New Zealand and the European Society of
Cardiology (Table 1).19,20 The maximum target doses were
those recommended by the guidelines and the maximum
tolerated dose was the maximum dose of a drug that an
individual could achieve. Patients who fulfilled one of
the contraindications or considerations and had a
legitimate reason for not reaching the maximum dose were
considered to be on ‘maximum tolerated doses’, if
continuing with the medication. Patients were receiving
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RESULTS
Of the 174 patients that were deemed eligible, 93 patients
were excluded as they either did not meet the inclusion
criteria or declined to participate in the study. On
completion of the recruitment period, 81 patients
consented to be enrolled in the study.
‘gold standard practice’, if they had a diagnosis
confirmed by an echocardiogram and were prescribed
either an angiotensin converting enzyme inhibitor or
angiotensin II receptor blocker and a beta-blocker.
The audit consisted of questions designed to
evaluate the level of evidence-based practice by
reviewing pharmacotherapy and non-pharmacotherapy
on admission and discharge based on study criteria
(Table 1).2,8,22 These results were then compared with
published evidence-based international practice. Patients
who did not suffer from dementia or other cognitive
impairment also had their health-related quality of life
and depression scores measured via the Minnesota
Living with Heart failure Questionnaire and the Geriatric
Depression Scale.
Patient’s pharmacotherapy, demographic data,
health-related quality of life and non-pharmacological
management were entered into the Department of Clinical
Pharmacology’s clinical information system. Data were
analysed using Excel 2003, the Social Package for the
Social Sciences (version 15), Access 2003 and Instat 3.0.
Descriptive statistics were used to describe the
demographic data presenting the data as proportions or
mean, medians and standard deviations with 95%
confidence intervals. The Social Package for the Social
Sciences (version 15) was also used to evaluate the
relationship between demographic data and comorbidity
on prescription of angiotensin converting enzyme
inhibitors and beta-blockers, through the student t-test
and Pearson’s chi-square correlations.
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Patient Characteristics
The median age of patients was 81 ± 9.4 years and 48%
were male. Most patients (n = 49; 63%), were in New York
Heart Association Class II or Class III heart failure.
English was the primary language for most patients (n =
73; 90%) and most patients lived at home alone (n = 33;
41%) or with a partner or other (n = 32; 40%). Seventy-six
(94%) patients had a past diagnosis of heart failure and
63 (78%) patients were diagnosed with heart failure on
admission. The main comorbidities were ischaemic heart
disease (75%), hyperlipidaemia (48%), hypertension (80%)
and atrial fibrillation (47%) (Table 2).
The mean number of comorbidities, medicines and
admissions in the previous year by age are shown in
Table 3. Patients were prescribed significantly more
medicines on discharge than on admission. This
significant difference was notable in patients aged 81 to
85 years (mean 10 medicines on discharge; 95%CI 7–16;
p = 0.005) and 86 to 90 years (mean 10 medicines on
discharge; 95%CI 7–10; p = 0.036). There were a total of
192 admission in the year prior to the study (mean 2
admissions/year), accounting for 1074 occupied bed-days
admissions and the median length of stay was 9 (2–65)
days (Table 3).
Blood pressure, weight and pathology in this cohort
were mostly within normal ranges. Quality of life using
the Minnesota Living with Heart Failure Questionnaire,
was reported as a median score of 38 (range 11–100; higher
score indicates perceived lower quality of life). The
median depression score using the Geriatric Depression
Scale was 5 (range 0–12) (Table 3).
Adherence to Heart failure Guidelines
In relation to diagnosis, an electrocardiogram was
performed in 96% of patients and 53% of patients had a
previous echocardiogram on record with 20% of
echocardiograms performed more than a year previously
(Table 2). There was no correlation between patients who
had an echocardiogram and the prescription of a beta-
blocker or an angiotensin converting enzyme inhibitor
and a beta-blocker on discharge. However, there was a
strong statistical correlation between patients who had
an echocardiogram and the prescription of an angiotensin
converting enzyme inhibitor (p = 0.005) on discharge.
The most commonly prescribed heart failure
medications on admission and discharge, were
angiotensin converting enzyme inhibitors (54% and 59%)
followed by beta-blockers (52% and 43%) (Table 4). Most
patients were discharged on a lower dose of beta-blockers
than recommended (17%; 95%CI 11–27; p ≤ 0.001) and
than on admission (36%; 95%CI 26–47; p ≤ 0.001).
In a multivariate analysis, only 25% of patients were
receiving ‘gold standard practice’ (echocardiogram plus
prescribed either an angiotensin converting enzyme
inhibitor or an angiotensin II receptor blocker and a beta-
blocker) and these patients were significantly ‘younger’
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(mean age 77 ± 11 years vs 84 ± 8.7 years; p = 0.027). In
contrast, this younger group on ‘gold standard practice’
had been admitted to hospital more often within the
previous year (p = 0.025). Younger age was also
associated with being prescribed maximum doses of
angiotensin converting enzyme inhibitors on admission
and discharge (median 78 ± 9 years vs 83 ± 9.5 years; p =
0.013). Beta-blockers (bisoprolol, carvedilol, metoprolol)
that have good evidence for use in heart failure were not
regularly prescribed either on admission (81%) or on
discharge (86%).
It was difficult to ascertain the true level of non-
pharmacological advice that had been given to the heart
failure patients because documentation and self-
reporting were the only sources of evidence for the
provision of self-care education and lifestyle changes.
Approximately, 20% of patients had some documentation
of education on regular exercise and 14% on salt
restriction. There was less documentation on fluid
restriction (7.4%), fluid action plan (4.9%), daily weight
and keeping a record or diary (6.2%) (Table 5).
International and National Comparisons
The utilisation of an echocardiogram as a diagnostic tool
was significantly lower in this study than the Euro Heart
Failure Survey (53% vs 66%; p = 0.002).2
There was no significant difference in prescription
of angiotensin converting enzyme inhibitors, between
this study and international studies either on admission
or discharge.2,3,5,6,8 However, angiotensin II receptor
blockers, were prescribed significantly more often in this
study than the Cardiac Awareness Survey and Evaluation
and the Euro Heart Failure Survey studies, on admission
(14% vs 4.3% and 4.5%; p < 0.001) and at discharge (11%
vs 4.3% and 4.5%; p < 0.001).2,21
Beta-blockers were prescribed more on admission
(52% vs 12% and 37%; p < 0.001) and on discharge in
this study than the Cardiac Awareness Survey and
Evaluation study (43% vs 12%; p < 0.001), but not more
than in the Euro Heart Failure Survey study.2,21
Spironolactone was used significantly more in this
study than in the Cardiac Awareness Survey and
Evaluation study on admission (16% vs 8.1%; p = 0.019)
and at discharge (24% vs 8.1%; p < 0.001).22 There were
no differences in prescription of spironolactone on
admission and at discharge compared to the Euro Heart
Failure Survey study.2
DISCUSSION
The results demonstrated no significant differences
between admission and discharge in prescription rates
of angiotensin converting enzyme inhibitors, angiotensin
II receptor blockers, beta-blockers, spironolactone and
digoxin in heart failure patients not enrolled in specialist
programs. There was a significant gap in the management
of these patients when compared to best practice
published in current guidelines.7-9 The results from our
study compared well with international and national
research, although robust measurement of the level of
non-pharmacological management was complicated by
the lack of measurable data (documented or recollected)
in more than 50% of patients.2,21
Adherence to Heart Failure Guidelines
The use of evidence-based pharmacotherapy is extremely
important in the management of heart failure as it can
contribute to reduced mortality and morbidity. The Euro
Heart Failure Survey is one of many studies that has
reported the under-use of angiotensin converting enzyme
inhibitors and beta-blockers. Our study also
demonstrated the under-use of angiotensin converting
enzyme inhibitors and beta-blockers in the community
and in hospital.2,23
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The rate of up-titration to maximum target doses of
the medications was also low. The medical records for
each patient were reviewed and showed few attempts at
up-titration of doses during the hospital admission either
for angiotensin converting enzyme inhibitors (2.5%) or
beta-blockers (8.6%). Many patients were discharged on
below maximum target doses without apparent reasons.
The Euro Heart Failure Survey study reported that
there was a greater probability of receiving recommended
pharmacotherapy if the patient was male and of a younger
age (below 70 years).2,23 We found no significant
influence of age or gender on prescription of angiotensin
converting enzyme inhibitors or beta-blockers on
discharge. The small number of patients included in the
study could explain this and that the ranges of ages in
this study included very few patients younger than 70
years of age.2,23 However, age did seem to influence the
probability that the patient was on a beta-blocker on
discharge (p = 0.05). Forty-three per cent of patients were
prescribed beta-blockers on discharge and of these 86%
were prescribed beta-blockers that are specifically
recommended for heart failure (bisoprolol, carvedilol,
metoprolol) and the remainder were prescribed non-
selective beta-blockers (e.g. atenolol) for management of
conditions other than heart failure.22
As for the non-pharmacological management of heart
failure, patient education was a challenge because many
patients lived alone and English was not the primary
language for 10% of patients, necessitating interpreters
or family members to translate lifestyle information. This
was an elderly group of patients characterised by memory
loss, confusion, fatigue and dementia with the majority
living alone. As non-pharmacological management has
semonstrated to have a major impact on preventing
hospital readmission, clinicians need to be encouraged
to document education interaction with the same priority
as other treatments.21,23
From the findings of our study, there are clearly many
opportunities for pharmacists to support evidence-based
management as part of the multidisciplinary heart failure
specialist team and independently within the hospital
and community. Within the hospital, pharmacists can be
involved in initiation of medications, titration and
monitoring, medicines counselling and education on
lifestyle changes. Within the community, pharmacists can
be involved in home medicines reviews/education and
counselling, titration and monitoring, reinforcing lifestyle
and self-care education, and family and carer support
and education.
The small sample size of patients included in this
study and the recruitment process may not have been
the most efficient way of screening for heart failure
patients due to the wide variation of admission diagnoses.
As only patients able to give consent were recruited,
there may have been bias to a healthier less cognitively
impaired group of heart failure patients.
In conclusion, the overall management of this group
of heart failure patients compared well to national and
international centres. However, management within the
hospital and the community falls short of many of the
recommended guidelines. Strategies to improve the
continuation of care from hospital to community, in the
areas of medication management review, dose titration,
monitoring, and counselling provide excellent
opportunities for the involvement of pharmacists as part
of a multidisciplinary heart failure management team.
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Dr Manya Angley, pharmacist and senior research fellow
with the Sansom Institute for Health in Pharmacy,
University of South Australia, is the new Associate Editor
of the Journal of Pharmacy Practice and Research. In
1989, after finishing her pre-registrant year at Flinders
Medical Centre, she became an academic at the School
of Pharmacy, University of South Australia and
commenced her postgraduate studies. Manya is a
teaching and research academic but also maintains her
practice in community and hospital pharmacy. Her primary
research interest revolves around medication management
along the continuum of care. She also leads the Autism
Research Group within the Sansom Institute, which
conducts research investigating aetiology and diagnosis
of autism and critically analyses its treatments. Manya is
married and has three children aged 13, 12 and 10 years.
Manya enjoys the outdoors, especially bike riding and
bushwalking, and her other interests include music,
theatre, food and wine. Welcome Manya!
Associate Editor
SHPA Research and Development Grants Program
RDGAC will be conducting a pre-conference workshop
in Perth on 5 November 2009. The first part of the
workshop will be a practical approach to constructing a
research application with participants working in groups
to develop a grant application based on a research case
scenario provided on the day. In the second part of the
workshop, group discussion will focus on opportunities
to foster research within hospital pharmacy departments.
Sponsors of the RDGAC program will be invited to join
the final session of the workshop. Members will have an
opportunity to share ideas and provide feedback to our
sponsoring companies. The workshop will be hosted by
the eminent South Australian pharmacologist Dr Sepehr
Shakib.
Manya Angley
In this edition of DrugScan we introduce some changes
in personnel and the topics covered. We bade farewell
to Karin Nyfort-Hansen (respiratory) and Gail Rowan
(oncology) and welcomed Megumi Kanaike (oncology)
and Leonie Abbott (emergency medicine). In view of
the expanding role of pharmacists in emergency
departments across the country, a new section dedicated
to emergency medicine has been introduced and replaces
the section on respiratory medicine.
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SHPA National Conference
CONGRATULATIONS TO THE RECENT RECIPIENTS OF SHPA GRANTS
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